Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 78 Records) |
| Query Trace: Recurrence and CYP2D6[original query] |
|---|
| Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. The pharmacogenomics journal 2018 04 18 (2): 201-208. Hwang G S, Bhat R, Crutchley R D, Trivedi M |
| CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. Scientific reports 2017 Aug 7 (1): 7727. Damkier Per, Kjærsgaard Anders, Barker Kimberly A, Cronin-Fenton Deidre, Crawford Anatasha, Hellberg Ylva, Janssen Emilius A M, Langefeld Carl, Ahern Thomas P, Lash Timothy |
| The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer. Pakistan journal of pharmaceutical sciences 2017 May 30 (3(Special)): 1095-1098. Zeng Yi, Huang Kai, Huang Weiw |
| CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast cancer research and treatment 2017 Nov 166 (1): 277-287. Hertz D L, Kidwell K M, Hilsenbeck S G, Oesterreich S, Osborne C K, Philips S, Chenault C, Hartmaier R J, Skaar T C, Sikora M J, Rae J |
| The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. OncoTargets and therapy 2017 10 5429-5437. Lu Junjun, Li He, Guo Peng, Shen Rui, Luo Yingbin, Ge Qiao, Shi Wenfei, Li Yan, Zhu Weika |
| CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy. Breast cancer research and treatment 2018 7 171 (3): 701-708. Jansen Laura E, Teft Wendy A, Rose Rhiannon V, Lizotte Daniel J, Kim Richard |
| Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. Advances in pharmacology (San Diego, Calif.) 2018 83 65-91. Cronin-Fenton Deirdre P, Damkier P |
| CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. Malaria journal 2018 Feb 17 (1): 57. Brasil Larissa W, Rodrigues-Soares Fernanda, Santoro Ana B, Almeida Anne C G, Kühn Andrea, Ramasawmy Rajendranath, Lacerda Marcus V G, Monteiro Wuelton M, Suarez-Kurtz Guilher |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical pharmacology and therapeutics 2018 2 103 (5): 770-777. Goetz Matthew P, Sangkuhl Katrin, Guchelaar Henk-Jan, Schwab Matthias, Province Michael, Whirl-Carrillo Michelle, Symmans W Fraser, McLeod Howard L, Ratain Mark J, Zembutsu Hitoshi, Gaedigk Andrea, van Schaik Ron H, Ingle James N, Caudle Kelly E, Klein Teri |
| Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers. Parasitology research 2019 2 118 (3): 1011-1018. Ariffin Norliza Mat, Islahudin Farida, Kumolosasi Endang, Makmor-Bakry Mo |
| CYP2D6 does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment. Personalized medicine 2020 6 17 (4): 261-270. Jorge-Aarón Rangel-Méndez, Rodrigo Rubi-Castellanos, de Jesús Ascencio-Montiel Iván, Esther Moo-Puc Ro |
| Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence. Antimicrobial agents and chemotherapy 2020 3 64 (5): . Silvino Ana Carolina Rios, Kano Flora Satiko, Costa Marcelo Azevedo, Fontes Cor Jesus Fernandes, Soares Irene Silva, de Brito Cristiana Ferreira Alves, Carvalho Luzia Helena, Sousa Tais Nobre |
| Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant). Medicine 2020 Feb 99 (8): e19083. Chan Carmen Wing Han, Miaskowski Christine, McCarthy Alexandra, Waye Mary Miu Yee, Yeo Winnie, So Winnie Kwok Wai, Choi Kai Chow, Tsui Stephen Kwok Wing, Chan Judy Yuet |
| Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer 2021 Mar 7 (1): 34. DeCensi Andrea, Johansson Harriet, Helland Thomas, Puntoni Matteo, Macis Debora, Aristarco Valentina, Caviglia Silvia, Webber Tania Buttiron, Briata Irene Maria, D'Amico Mauro, Serrano Davide, Guerrieri-Gonzaga Aliana, Bifulco Ersilia, Hustad Steinar, Søiland Håvard, Boni Luca, Bonanni Bernardo, Mellgren Gunn |
| The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China. Malaria journal 2021 Mar 20 (1): 160. Huang Herong, Dong Ying, Xu Yanchun, Deng Yan, Zhang Canglin, Liu Shuping, Chen Mengni, Liu Y |
| Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions. Pharmacogenomics and personalized medicine 2021 14 279-286. Jeiziner Chiara, Stäuble Céline K, Lampert Markus L, Hersberger Kurt E, Meyer Zu Schwabedissen Henriette |
| Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics. Frontiers in oncology 2021 12 11 738222. Pang Hui, Zhang Guoqiang, Yan Na, Lang Jidong, Liang Yuebin, Xu Xinyuan, Cui Yaowen, Wu Xueya, Li Xianjun, Shan Ming, Wang Xiaoqin, Meng Xiangzhi, Liu Jiaxiang, Tian Geng, Cai Li, Yuan Dawei, Wang X |
| Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China. Malaria journal 2021 11 20 (1): 448. Dong Ying, Huang Herong, Deng Yan, Xu Yanchun, Chen Mengni, Liu Yan, Zhang Cangl |
| Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. Scientific reports 2021 Jan 11 (1): 415. Sanchez-Spitman A B, Swen J J, Dezentjé V O, Moes D J A R, Gelderblom H, Guchelaar H |
| Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. World journal of clinical oncology 2022 9 13 (8): 712-724. Tan Ern-Yu, Bharwani Lavina, Chia Yee-Hong, Soong Richie C T, Lee Sherylyn S Y, Chen Juliana J C, Chan Patrick M |
| Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. Journal of ovarian research 2022 5 15 (1): 50. Marchocki Zibi, Tone Alicia, Virtanen Carl, de Borja Richard, Clarke Blaise, Brown Theodore, May Taym |
| (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. Journal of personalized medicine 2022 4 12 (4): . Almeida Thais, Schroth Werner, Nardin Jeanine, Mürdter Thomas E, Winter Stefan, Picolotto Solane, Hoppe Reiner, Kogin Jenifer, Gaio Elisa, Dasenbrock Angela, Skrsypcsak Raquel Cristina, de Noronha Lucia, Schwab Matthias, Brauch Hiltrud, Casali-da-Rocha José Claud |
| Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis. Travel medicine and infectious disease 2022 4 48 102333. Park Yoon-A, Park Ki Hyun, Yoon Ha Young, Yee Jeong, Gwak Hye S |
| Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022 12 10781552221146531. El Desoky Ehab S, Taha Amira F, Mousa Heba Salah, Ibrahim Abeer, Saleh Medhat A, Abdelrady Mohamed A, Hareedy Mohammad Sal |
| The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC cancer 2022 Oct 22 (1): 1067. Ismail Al-Khalil Wouroud, Al-Salhi Lana, Rijjal Sara, Aljamali Majd, Youssef Lama |
| Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients. Malaria journal 2022 Oct 21 (1): 289. Choi Sungim, Choi Heun, Park Seong Yeon, Kwak Yee Gyung, Song Je Eun, Shin So Youn, Baek Ji Hyeon, Shin Hyun-Il, Cho Shin-Hyung, Lee Sang-Eun, Kwon Jeong-Ran, Park Sookkyung, Kim Miyoung, Oh Hong Sang, Kim Yong Chan, Kim Min Jae, Yeom Joon-S |
| Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Expert reviews in molecular medicine 2022 1 24 e1. Chan Carmen Wing Han, Li Caixia, Xiao Eleven Jinnan, Li Minjie, Phiri Patrick Gladson McLeywick, Yan Tingting, Chan Judy Yuet |
| Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer. Breast cancer research and treatment 2023 4 . Souwer E T D, Sanchez-Spitman A, Moes D J A R, Gelderblom H, Swen J J, Portielje J E A, Guchelaar H J, van Gelder |
| Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records. Breast cancer research and treatment 2023 3 . Thorén Linda, Margolin Sara, Eliasson Erik, Bergh Jonas, Lindh Jonatan |
| Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 2 160 114369. Agema Bram C, Buijs Sanne M, Sassen Sebastiaan D T, Mürdter Thomas E, Schwab Mathias, Koch Birgit C P, Jager Agnes, van Schaik Ron H N, Mathijssen Ron H J, Koolen Stijn L |
- Page last reviewed:Feb 1, 2024
- Content source: